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Abstract
Objectives—The potential for beneficial effects of adipose-derived stem cells(ASCs) on 
myocardial perfusion and left ventricular dysfunction in myocardial ischemia(MI) has not been 
tested following intravenous delivery.
Methods—Surviving pigs following induction of MI were randomly assigned to 1 of 3 different 
groups: the placebo group (n=7), the single bolus group (SB)(n=7, 15×107 ASCs), or the divided 
dose group (DD)(n=7, 5×107 ASCs/day for three consecutive days). Myocardial perfusion defect 
area and coronary flow reserve (CFR) were compared during the 28-day follow-up. Also, serial 
changes in the absolute number of circulating CD4+T and CD8+T cells were measured.
Results—The increases in ejection fraction were significantly greater in both the SB and the DD 
groups compared to the placebo group (5.4±0.9%, 3.7±0.7%, and -0.4±0.6%, respectively), and 
the decrease in the perfusion defect area was significantly greater in the SB group than the placebo 
group (-36.3±1.8 and -11.5±2.8). CFR increased to a greater degree in the SB and the DD groups 
than in the placebo group (0.9±0.2, 0.8±0.1, and 0.2±0.2, respectively). The circulating number of 
CD8+T cells was significantly greater in the SB and DD groups than the placebo group at day 
7(3,687±317/μL, 3,454±787/μL, and 1,928±457/μL, respectively). The numbers of small vessels 
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were significantly greater in the SB and the DD groups than the placebo group in the peri-infarct 
area.
Conclusions—Both intravenous SB and DD delivery of ASCs are effective modalities for the 
treatment of MI in swine. Intravenous delivery of ASCs, with its immunomodulatory and 
angiogenic effects, is an attractive noninvasive approach for myocardial rescue.
Keywords
adipose stem cell; intravenous injection; myocardial perfusion; myocardial infarction; ventricular 
dysfunction
INTRODUCTION
Ischemic heart disease is the leading cause of death in the United States in spite of rapid 
advances in the treatment of coronary artery disease.(1) The concept of using stem and 
progenitor cells isolated from adult tissues to treat patients with myocardial ischemia (MI) is 
gaining momentum. Several clinical trials involving skeletal myoblasts,(2,3) bone marrow-
derived progenitor cells,(4-6) and peripheral blood progenitor cells(7,8) have shown 
encouraging results for limiting myocardial damage and improving myocardial function. 
Therapies employing adipose-derived stem cells (ASCs) have also emerged as a practical 
approach to promote recovery. ASCs are mesenchymal cells that share many properties in 
common with bone marrow-derived mesenchymal stem cells (MSCs), and reside in the 
stromal-vascular fraction of adipose tissue.(9-11) Therapeutic use of autologous ASCs for 
cardiac repair is particularly practical due to the ready availability of these cells in large 
quantities for therapeutic injection. Many studies have employed invasive techniques to 
deliver stem or progenitor cells directly into a coronary artery or the myocardium. Our 
recent data demonstrating that ASC delivered intravenously had systemic activity, including 
effects on bone marrow progenitors and adipose tissue mass as well as pulmonary 
endothelium,(12) suggested the hypothesis that intravenous ASC delivery would also be a 
particularly feasible approach to the early provision of stem cells in acute MI, and would 
demonstrate significant rescue of myocardial function and perfusion without a need for 
targeted delivery. In the current study, we observed the distribution of intravenously injected 
human ASCs 2 hrs, 14 days, and 28 days after inducing MI in swine. We then investigated 
the efficacy of single bolus vs. 3 consecutive divided intravenous injections of human ASCs 
following induction of MI.
METHODS
Animal Model
Animal handling followed the recommendations of the National Institutes of Health (NIH) 
guide for the care and use of laboratory animals. The study protocol was approved by the 
Institutional Animal Care and Use Committee at the Indiana University School of Medicine.
Twenty seven pathogen-free (Michigan State University) Yorkshire cross domestic pigs (28 
to 38 kg) of mixed gender were employed. MI was induced by angioplasty balloon inflation 
in the mid left anterior descending coronary artery (LAD). Pigs surviving acute MI were 
Jun Hong et al. Page 2
Catheter Cardiovasc Interv. Author manuscript; available in PMC 2018 April 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
randomly assigned to 1 of 3 groups: placebo (n=7, 3 mL PBS), single bolus (n=7, 15 × 107 
hASCs), or divided dose (n=7, 5 × 107 hASCs/day for three consecutive days) (Fig. 1). To 
examine hASC distribution and persistence, two pigs were sacrificed 2 hrs and 14 days after 
systemic injection of 15 × 107 hASCs.
Aspirin 325 mg and clopidogrel 75 mg were given orally 24 hrs prior to anterior MI, 
followed by aspirin 81 mg daily. Unfractionated heparin (300U/kg) was administered 
intravenously and repeated to maintain the ACTe300 sec. General anesthesia was induced by 
intramuscular telazol (4.4 mg/kg), xylazine (2.2 mg/kg), ketamine (2.2 mg/kg) and atropine 
(0.05 mg/kg). The animal was then intubated and ventilated with a closed volume cycle 
respirator, and anesthesia maintained with isoflurane (1.5~2.5%) and oxygen (2 L/min) 
while maintaining euthermia. Buprenex (0.01mg/kg) was administered for analgesia.
Myocardial Infarction Induction and Intracoronary Doppler Measurements
Arterial access was obtained via the femoral artery with a cutdown technique. Left coronary 
angioplasty was performed using a 7F Hockey-stick guiding catheter (Boston Scientific 
Corp., Natick, MA). Continuous hemodynamic monitoring was performed via an 8F femoral 
artery sheath. After baseline left coronary angiography, MI was induced by inflating a 
Quantum Maverick® 3.5× 8 mm over-the-wire balloon (Boston Scientific Corp.) for 60 
minutes in the LAD immediately distal to the first dominant septal perforator. To minimize 
ventricular arrhythmias, intravenous amiodarone was administered prior to balloon inflation 
(75 mg/10 min) and continued at 1 mg/min for 60 min post occlusion.(13) Breakthrough 
arrhythmias were terminated with DC cardioversion when necessary (Medtronic, 
Minneapolis, MN). Coronary angiography was performed again after balloon inflation and 
at euthanasia. Serum cardiac troponin-I was measured 48 hrs after MI by chemiluminescent 
immunoassay (Immulite®, Siemens AG, Munich, Germany) validated for a porcine model 
(ANTECH® Diagnostics Inc., Morrisville, NC).
Coronary microvascular flow was measured by intracoronary Doppler wire (Flowire, 
Volcano Corp, Rancho Cordova, CA) at baseline and 2 hr post-MI. Nitroglycerin 0.2 mg was 
injected into the intracoronary circulation to achieve maximal epicardial coronary artery 
dilation without significantly affecting coronary microcirculation. A Doppler guidewire was 
positioned in the LAD just distal to the first dominant septal perforator. The average peak 
flow velocity was measured at baseline and during maximal hyperemia induced by 
intracoronary bolus injection of 30 μg adenosine.(14,15) Doppler measurements were 
repeated at least three times, and the averaged. As a surrogate for microvascular integrity, 
coronary flow reserve (CFR) was determined as the adenosine-induced average peak flow 
velocity divided by the baseline average peak flow velocity; this was repeated 28 days later 
with an identically positioned Doppler wire, as confirmed by two orthogonal views.
Isolation and Culture of Human Adipose Stromal Cells
Human subcutaneous abdominal adipose tissue samples were obtained from 2 female 
volunteers (age 23 and 38) undergoing liposuction. ASCs isolated from each volunteer were 
evenly distributed between the single bolus and divided dose groups. Adipose tissue was 
agitated in 1 mg/ml Collagenase Type I (Worthington Biochemical, Lakewood, NJ) prepared 
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in DMEM/F12 medium (Invitrogen, Carlsbad, CA), supplemented with 10% FBS, 100 
units/mL penicillin and 100 μg/mL streptomycin, for 2 hours at 37°C followed by 
centrifugation at 300g for 8 minutes to separate the stromal cell fraction (pellet) from 
adipocytes.(16) The pellet was resuspended in DMEM/F12 medium supplemented with 10% 
FBS filtered through 250 μm Nitex (Sefar America Inc., Kansas City, MO) and centrifuged 
at 300g for 8 minutes. To eliminate erythrocytes the pellet was treated with RBC lysis buffer 
(154 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) for 10 minutes. The final pellet was 
resuspended and cultured in EGM-2MV media (Cambrex, East Rutherford, NJ). ASC 
monolayers were passaged when 60-80% confluent and used at passage 3-4. Cell viability 
was evaluated by Trypan blue staining. For single bolus 15 × 107 hASCs injection, cells 
were resuspended in 9 mL of PBS with 100U/mL unfractionated heparin and autologous 
swine serum (450 μL) immediately before delivery, and injected 2 hours post-MI. For the 
divided dose 5 × 107 hASCs group, cells were resuspended in 3 mL of PBS with 100U/mL 
unfractionated heparin and autologous swine serum (150 μL) immediately before delivery; 
ASCs were injected 2, 24, and 48 hours after MI. The suspension was infused at 2 mL/min 
via ear vein catheter.
Contrast-Enhanced Echocardiography and Myocardial Perfusion Echocardiography
Contrast-enhanced 2D and 3D echocardiography and myocardial contrast echocardiography 
(MCE) were performed prior to MI, 2 days after MI, and prior to sacrifice at day 28. Pigs 
were anesthetized with isoflurane and imaged in right lateral decubitus position using a 
phased-array (S5-1, 1~5 MHz) and matrix-array (X3-1, 1~3 MHz) transducer connected to 
an iE33 system (Philips Medical System, Andover, MA). Microbubbles were prepared by 
sonication of a gas-saturated aqueous suspension of distearoylphosphatidylcholine (2 
mg/mL) and polyoxyethylene-40-stearate (1 mg/mL)(17), and were intravenously infused 
during 3D image acquisition using harmonic imaging to optimize left ventricular (LV) 
endocardial border delineation (Supplemental Fig. 1A,B). The endocardial border at end-
systole and end-diastole was manually traced in the 4 chamber apical view from 3D images, 
and LV end-diastolic volume, end-systolic volume, stroke volume, and ejection fraction (EF) 
were obtained (Supplemental Fig. 1C~E). Wall thickening and fractional shortening were 
measured from 2D-guided M-mode recordings (Supplemental Fig. 2A~D). For additional 
quantification of wall motion, the 16-segment model was used, adding segmental wall 
motion scores of 1=normal, 2=hypokinesis, 3=akinesis, and 4=dyskinesis (Supplemental 
Fig. 2E).(18,19) Wall motion score index (WMSI) was calculated as the sum of the scores of 
the segments divided by the number of the segments evaluated. Data were analyzed by two 
readers who were blinded to the randomization using QLab software (Version 7.0, Philips 
Medical System, Andover, MA). Interobserver correlation was 0.82 (P<0.001), and 
intraobserver correlation on 15 randomly selected cases were 0.89 and 0.84 (P<0.001 for 
both) for the two readers.
To assess myocardial perfusion, a microbubble suspension (5 × 107 mL-1) was infused 
intravenously at 1.5 mL·min-1 to produce myocardial opacification with minimal inferior 
wall attenuation. MCE was performed in the parasternal short-axis plane just below papillary 
muscle level using power modulation at a mechanical index of 0.16. End-systolic images 
were acquired after a 5-frame high-power (mechanical index 1.2) sequence. The percent area 
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of microbubble perfusion was measured with ImageJ software (1.43u, National Institute of 
Health, USA). The area at risk (AAR) during LAD coronary occlusion and the region void 
of perfusion at 2 and 28 days after MI were each measured by two blinded readers, 
averaged, and expressed as percentages of the total LV area. Interobserver correlation for 
AAR measurements was 0.81 (P<0.001) and intraobserver correlation for 15 randomly 
selected cases was 0.86 and 0.82 (P<0.001 for both).
Analysis of Lymphocyte, Monocyte, and Granulocyte Populations in Peripheral Blood
Blood samples were obtained and collected into test tubes containing heparin pre-MI, and 
day 2, 7, and 28 post-MI. Within 1 hr of collection, peripheral blood mononuclear cells 
(PBMNCs) were isolated by density gradient centrifugation using Ficoll-Paque plus® 
(Amersham Biosciences Corp., NJ). The number of lymphocytes, monocytes, and 
neutrophils in PBMNCs were measured using Coulter LH®755 automated hematology 
analyzers (Beckman Coulter Inc., CA). Erythrocytes were lysed by incubating in 10 mL of 
red blood cell lysis buffer solution (154 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA). 
Lymphocyte subsets analyzed were helper T cells (CD3+CD4+) or cytotoxic T cells 
(CD3+CD8+). Cells were stained with fluorochrome-conjugated monoclonal antibodies 
against CD8-PE (BD, Franklin Lakes, NJ), CD3-FITC (BD), and CD4-PE (BD) for 20 min 
at 4°C. Pelleted leukocytes were fixed in 2% paraformaldehyde and analyzed by flow 
cytometry (BD). Expression levels were analyzed using CellQuest™ Pro software (BD).
DNA Isolation and Real-Time PCR Assays for Alu Sequences
Heart, lung, liver, pancreas, spleen, kidney, and bone marrow were isolated and stored at 
-80°C. Samples (25 mg) were thawed and homogenized with a BeadBeater-8 (Biospec, 
Bartlesville, OK). A DNA extraction kit was used for DNA isolation (QIAGEN, Valencia, 
CA). Standard curves were generated for PCR by addition of known numbers of hASCs 
(0~105) into pig tissue samples prior to homogenization. Real-time PCR assays for Alu 
sequences(20) were performed in a reaction volume of 50 μL that contained 25 μL Taqman 
Universal PCR Master Mix (Applied Biosystems, Foster City, CA), 900 nM each of the 
forward (5’-CAT GGT GAA ACC CCG TCT CTA-3’) and reverse primers (5’-GCC TCA 
GCC TCC CGA GTA G-3’), 250 nM TaqMan probe (5’-FAM-ATT AGC CGG GCG TGG 
TGG CG-TAMRA-3’), and 200 ng target template. Reactions were incubated at 50°C for 2 
min and 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. Cycle-
dependent amplification for each tissue sample was used to estimate the number of hASCs. 
All real-time PCR assays were performed in duplicate and average values presented.
Statistical Analysis
Continuous variables are presented as mean±SEM. Variables measured repeatedly were 
compared using repeated-measures ANOVA. Kruskal-Wallis test or one-way ANOVA with 
Tamhane posthoc analysis was used for multiple comparisons. Mann-Whitney U test was 
used to compare 2 groups, and Spearman’s correlation was calculated with SPSS® 12.0 
software (SPSS Inc, Chicago, IL). P <0.05 was considered statistically significant.
Staining and Post-MI Electrocardiographic Monitoring are found in the Detailed 
Supplemental Methods
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RESULTS
Study Animals
No significant difference in body weights were noted among the 3 groups at baseline (Table 
1). Ventricular tachycardia or fibrillation occurred during each LAD occlusion. Intractable 
ventricular fibrillation with unsuccessful cardioversion occurred in 4 pigs, and another 2 pigs 
died suddenly within 48 hrs after MI (22% cumulative attrition rate). Cardiac troponin-I 
levels were increased in all pigs 48 hrs after MI without significant differences among 3 
groups (Table 1).
Changes in Left Ventricular Function
LVEF showed no significant difference among 3 groups before and 2 days after MI. 
However, LVEF was significantly greater in the single bolus group compared to the placebo 
group 28 days after MI (Table 1). The changes in LVEF between 2 and 28 days after MI 
showed significant increases in both the single bolus and the divided dose groups compared 
to the placebo group (Table 1). While no significant differences were noted in inferior wall 
thickening during the 28 day follow-up, anterior wall thickening (%) was significantly 
greater in the single bolus group compared to the placebo group (Table 1; Supplemental Fig. 
2B,C). After normalizing anterior wall thickening (%) with inferior wall thickening (%), 
anterior and inferior wall thickening ratio at day 28 was greater in the single bolus group 
compared to the placebo group (Table 1). WMSI was similar among 3 groups at Day 2, but 
WMSI was significantly lower in the single bolus (P=0.002) and the divided dose groups 
(P=0.002) than the placebo group at day 28 (Supplemental Fig. 2F).
Myocardial Microvascular Perfusion and Coronary Flow
The mean AAR, illustrated in Supplemental Fig. 3A, was 29.7±2.3% in the single bolus 
group and was not different between groups, and the mean perfusion defect area in the single 
bolus group decreased from 25.0±1.7% at Day 2 to 14.3±1.3% at Day 28 (Supplemental Fig. 
3B). The perfusion defect area (%) at day 28 revealed a strong correlation to the nonviable 
myocardial area (%) in TTC staining (r=0.81, P<0.001) (Supplemental Fig. 3C,D). When the 
change in perfusion defect area from day 2 to day 28 was normalized with the AAR, the 
decrease (improvement) in the perfusion defect area was significantly greater in the single 
bolus group compared to the placebo group (-36.3±1.8 and -11.5±2.8, P=0.021, 
respectively) (Fig. 2).
CFR decreased considerably in all 3 groups 2 hours after MI, while the values of CFR at day 
28 were significantly greater in the single bolus and the divided dose groups compared to the 
placebo group (2.3±0.1, 2.1±0.1, and 1.6±0.1, respectively) (Fig. 3A). When the changes in 
CFR from 2 hr post-MI to day 28 were compared, the increases in the CFR were 
significantly greater in the single bolus and the divided dose groups than the placebo group 
(0.9±0.2, 0.8±0.1, and 0.2±0.2, respectively) (Fig. 3A). Moreover, the decreases in the 
perfusion defect area (%) during the 28 day interval correlated with the increases in CFR (r= 
-0.71, P=0.001) (Fig. 3B).
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Immune Modulation
No significant differences in total neutrophil, monocyte, or lymphocyte numbers were 
observed among groups before or after MI (Supplemental Fig. 4A~D). However, analysis of 
subpopulations revealed that absolute numbers of CD8+T cells dropped significantly post-
MI in the placebo group at day 7 (1,928±457/μL in the placebo group, 3,687±317/μL in the 
single bolus group, and 3,454±787/μL in the divided dose group) (Supplemental Fig. 4E,F), 
contributing to a significant increase in the CD4+/CD8+ T cell ratio seen in the placebo 
group but suppressed in the single bolus and divided dose groups (175±17, 88±5, and 
98±16, respectively) (Fig. 4).
Electrical Ventricular Stability after MI
Most PVCs occurred within 10 hours post-MI (Fig. 5), and administration of ASC resulted 
in significant suppression of PVCs per total beats (%) in the divided dose group when 
compared with the placebo group at 5 hours (3.8±0.4% and 5.3±0.2% respectively), 6 hours 
(2.7 ± 0.3% and 5.0±0.4% respectively), and 7 hours post-MI (2.2±0.2% and 4.1±0.1% 
respectively) (Fig. 5). Also, significant decrease in PVCs (%) was noted in the single bolus 
group vs. the placebo group 7 hour post-MI (2.7±0.4% and 4.1±0.1% respectively) (Fig. 5).
Comparison of Angiogenesis and Nerve Sprouting
Significant increases in the number of SMA+ small vessels were found in the single bolus 
group when compared to the placebo group in non-infarct (49±3/mm2 and 38±5/mm2, 
respectively), peri-infarct (40±5/mm2 and 25±3/mm2, respectively), and infarct areas 
(28±4/mm2 and 15±2/mm2, respectively) (Fig. 6A,B)(Supplemental Fig. 5A~C). Also, 
significant increases in the number of SMA+ small vessels were noted in the divided dose 
group when compared to the placebo group in both peri-infarct (42±4/mm2 and 25±3/mm2, 
respectively) and infarct areas (27±2/mm2 and 15±2/mm2, respectively) (Fig. 6A). No 
significant difference in the number of SMA+ large vessels was found among the groups 
(Fig. 6B).
Remarkable increases in GAP43+ nerve density were found in the single bolus group 
(P=0.031) and the divided dose group (P=0.005) when compared to placebo in the peri-
infarct areas (Fig. 6C)(Supplemental Fig. 5D~F). No significant difference in the GAP43+ 
nerve density was found among 3 groups in the non-infarct areas. The most active 
angiogenesis and nerve sprouting in the single bolus and the divided dose group occurred in 
the basal, mid-anteroseptal, and anterolateral segments, corresponding to regions where 
perfusion by MCE increased from day 2 to day 28. Serial sections demonstrated that 
GAP43+ nerve sprouting were found most prominently around SMA+ small vessels in the 
peri-infarct areas (Supplemental Fig. 5G~I).
Tissue Distribution of hASCs after Systemic Injection
Real-time PCR for human DNA Alu elements was examined in multiple tissues 2 hour, 14 
and 28 days after 15 × 107 hASC injection. Heart was sectioned into 5 short-axis slices each 
with 4 or 6 segments (Supplemental Fig. 2E), and samples from heart, lung, liver, kidney, 
pancreas, spleen, and bone marrow were examined for hASC presence. Two hours after 
intravenous injection, most (85.7%) hASCs were detected in the lungs (Fig. 7A), where 
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ASC numbers decreased significantly 14 days after cell injection. A few hASCs were 
detected in the peri-infarct area 2 hours after systemic injection of 15 × 107 cells (Fig. 7B), 
but no hASC were found at day 28 (Fig. 7C). hASCs were also readily visualized in lung 2 
hours after systemic injection but not at day 28 (Fig. 7D, E).
DISCUSSION
This is the first study to evaluate the time course of LV contractile function and 
microvascular integrity after intravenous delivery of human ASCs in a swine MI model. We 
have demonstrated the feasibility of xenogeneic transplantation of ASCs in the absence of 
specific immunosuppression, and shown for the first time that intravenous ASC injection 
either as a single bolus or divided dose (over 3 consecutive days) improves LVEF and CFR, 
and significantly reduces the extent of myocardial infarction at a 28 day follow-up. We 
propose that modulation in inflammation manifested by the CD4+/CD8+T cell ratio, as well 
as the increase in local angiogenesis and myocardial nerve sprouting after MI contribute to 
limitation in infarction, with improvement in myocardial and microvascular function. 
Although most intravenously injected ASCs were trapped in the lung and disappeared within 
14 days after cell injection, the beneficial effects persisted at day 28. We hypothesize that 
intravenous injection of ASCs could be utilized as a potential therapeutic option in patients 
with MI.
Although many pre-clinical and clinical trials have explored intracoronary, endocardial, or 
epicardial routes for delivery of stem cells after ischemic myocardial damage (2-7,21,22), 
these methods of delivery are more invasive than intravenous delivery of stem cells. 
However, many studies demonstrating functional benefits of invasive cell delivery do not 
have well-documented data regarding the fate of those delivered cells.(2-7,23) In our 
previous study, we delivered PBMNCs via intracoronary, epicardial, and retrograde coronary 
venous routes, and noted that even with these local delivery routes, most delivered PBMNCs 
were found in the lung within 1 hour after cell delivery(13); this prompted us to hypothesize 
that cells distributed to the lung might in fact contribute significantly to the beneficial effects 
observed in numerous studies. Our recent study of intravenous ASC delivery in a mouse 
model of COPD clearly demonstrated effects of the cells on multiple tissues, including lung, 
bone marrow, and fat.(12) This effect has also been suggested to explain cardiac effects of 
bone-marrow derived MSCs, which were shown to secrete factors such as TSG-6 while 
entrapped in lung tissue following systemic delivery,(20) and more recently also were shown 
to modulate lung pathology via TSG-6 secretion.(24) Paracrine effects by delivered cells 
probably played an important role in inhibiting further myocardial damage or progression of 
cardiac remodeling in the early period after ischemic myocardial damage in these cardiac 
studies.(2-7,23) The outcomes of this study support the notion that ASCs which lodge in the 
pulmonary circulation secrete paracrine factors that are delivered directly to the LV on their 
first-pass, where they produce cardioprotective effects. In our pilot experiment with rat 
myocardial infarction model, injecting cell-free supernatant from the cultured hASC 
monolayers containing factors such as VEGF, HGF, TGF-beta, and bFGF did not improve 
left ventricular function as prominent as giving hASCs intravenously (Supplemental Fig. 6). 
We assume that even though intravenously injected hASCs disappear within 2 weeks from 
pulmonary vessels, injected hASCs continuously secrete angiogenic and anti-apoptotic 
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factors into circulation in the early period after myocardial ischemia, thereby demonstrating 
significant improvement in left ventricular function after myocardial damage in this study.
LV remodeling, which includes infarct expansion and LV dilatation, starts very early after 
MI,(25-28) and is an indication of poor prognosis and occurs despite coronary 
revascularization.(26) While end-diastolic and end-systolic volumes increased post-MI in 
the placebo group, these adverse changes were remarkably ameliorated in the single bolus 
group during the 28 day follow-up after MI, with more prominent decreases in the end-
systolic volume, indicating beneficial effects of early intravenous ASC injection on both 
systolic function and LV remodeling in this study (Supplemental Fig. 1C,D). Significant 
functional improvement in stroke volume was observed in the single bolus group when 
compared to the placebo group at day 28, indicating beneficial effects of early intravenous 
ASC injection in LV contractile function (Supplemental Fig. 1E).
MCE is a useful technique for evaluating myocardial microvascular perfusion during acute 
coronary occlusion, as well as eventual infarct size. We demonstrated a significant reduction 
in the post-MI perfusion defect in animals receiving single bolus ASCs (Fig. 2, 
Supplemental Fig. 3B). This study also showed the expected correlation between the 
perfusion defect area (%) and the nonviable myocardial area in TTC staining (%) (r=0.81, 
P<0.001), suggesting that improvement in vascularization in border zones resulted in smaller 
infarct size. Moreover, the decreases in the perfusion defect area (%) during the follow-up 
correlated with the increases in CFR (r=-0.71, P=0.001) which indicate that the decreases in 
perfusion defect area indeed represent improvement in myocardial microvascular flow. 
Nerve sprouting and angiogenesis contribute to the improvement in LV contractile function 
and microvascular flow, and significant increases in the nerve density and the number of ±-
actin+ small vessels colocalized at the border where perfusion by MCE increased during the 
follow-up in the ASC injected groups (Supplemental Fig. 5). This suggests that real-time 
MCE could be used as a valuable noninvasive tool to evaluate angiogenesis induced by ASC 
delivery in clinical practice.
T cells play an important role in regulating the early inflammatory responses to myocardial 
ischemia/reperfusion injury.(29) MI is associated with an accumulation of lymphocytes such 
as CD4+T and CD8+T cells in damaged myocardium,(29) and inhibition of T cells by 
cyclosporine A and tacrolimus has been demonstrated to protect the heart against ischemia/
reperfusion injury.(30,31) ASCs are known for immunomodulating effects,(9) and it is 
interesting to note that the transplantation of ASCs in this study prevented sequestration of 
circulating CD8+T cells 7 days after MI, thereby preventing the post-MI increase in 
CD4/CD8 ratio in both the single bolus and the divided dose groups (Fig. 4, Supplemental 
Fig. 4E,F). This alteration in the balance of the T cell ratio may have contributed to the 
limitation of myocardial injury by ASC.
There are a few limitations in this study. We injected xenogeneic ASCs to allow specific 
evaluation of the effect of human ASCs in this large animal model of infarction. While we 
correctly anticipated that xenogeneic ASC transplant would be tolerable given the 
immunomodulatory effects of this cell type, we recognize the remaining uncertainty whether 
allogeneic or autologous ASCs might provide greater functional rescue than xenogeneic 
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ASCs. We used 15 × 107 hASCs based on pilot dose escalation studies involving direct 
coronary artery infusion, and it is unknown whether systemic injection of higher number of 
ASCs could provide superior improvement in damaged myocardium. Moreover, the follow-
up duration was 28 days in this study, and a long-term follow-up could be conducted to 
confirm a sustained benefit from ASC therapy. We could not use fresh, uncultured cells in 
this study because not enough hASC could be obtained for intravenous injections in swine 
myocardial infarction model, and proliferative and differentiation abilities of stem cells 
gradually decrease at their later passages.
CONCLUSIONS
Data from Phase I clinical trials such as the APOLLO(32) and the PRECISE trials(33) have 
been presented recently. The APOLLO trial in 14 patients with ST-elevation MI showed a 
reduction in infarct size after intracoronary injection of autologous ASCs.(32) The 
PRECISE trial in 27 patients with non-revascularizable ischemic myocardium showed a 
reduction in infarct size after direct injection of autologous ASCs.(33) These 2 clinical trials 
used invasive intracoronary and intramyocardial delivery methods. Our preclinical study 
suggests that noninvasive intravenous delivery of ASCs may also prove effective and 
feasible in ameliorating ischemia/reperfusion induced myocardial damage, and represents an 
attractive noninvasive approach that will expand the potential clinical application of ASC 
therapy for myocardial tissue rescue in patients with acute MI.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Study protocol. Swine were randomized into 3 groups (placebo, single bolus, and divided 
dose). Echocardiography, MCE, CFR, lymphocyte subpopulation analysis were done before 
MI and 2 and 28 days after MI. CFR was measured before MI, 2 hrs and 28 days after MI.
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Fig. 2. 
The perfusion defect area was normalized with the baseline AAR, and the decrease in the 
perfusion defect area from day 2 to day 28 was significantly greater in the single bolus group 
compared to the placebo group.
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Fig. 3. 
(A) CFR revealed significant increases in the single bolus and the divided dose groups than 
the placebo group (*P<0.01 and **P<0.05). (B) The decreases in the perfusion defect area 
(%) during the follow-up correlated with the increases in CFR.
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Fig. 4. 
Serial changes in CD4/CD8 ratio in the placebo group showed significant increases when 
compared to the single bolus and the divided dose groups (P=0.016).
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Fig. 5. 
PVCs(%) in each hour after MI. Most of PVCs occurred within 10 hours after MI, and the 
serial changes in PVCs(%) in the single bolus and divided dose groups showed significant 
decreases when compared to the placebo group especially at 5, 6, and 7 hours after MI 
(*P<0.05).
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Fig. 6. 
(A) Significant increases in the number of ±-actin+ small and collapsed vessels were found 
in the single bolus group in the non-infarct (*P<0.05), peri-infarct (*P<0.05), and infarct 
areas (*P<0.05). Significant increases in the number of ±-actin+ small and collapsed vessels 
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were also found in the divided dose group in the peri-infarct (**P<0.01) and infarct areas 
(**P<0.01). (B) No significant differences in the number of ±-actin+ large vessels were 
found among 3 groups. (C) Significant increases in the GAP43+ nerve density were found in 
the single bolus (*P<0.05) and the divided dose group (**P=0.005) when compared to the 
placebo group in the peri-infarct areas.
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Fig. 7. 
Tissue distribution after systemic injection of 15 × 107 hASCs. (A) More than 85% of 
hASCs were found in the lung 2 hour after intravenous injection, and no large number of 
hASCs was detected 14 days after intravenous injections. (B) Identification of hASC 
presence by immunostaining (20x) in the periinfarct area 2 hours after intravenous injection 
of 15 × 107 cells. Bars=50μm. (C) No hASCs were found in the heart 28 days after 
intravenous injection. (D) hASCs were present in the interstitial space in the lung 2 hours 
after intravenous injection of 15 × 107 cells. (E) No human ASCs were found in the lung 28 
days after intravenous injection.
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Table 1
Comparison of the Body Weight, Troponin-I, and Echocardiographic Parameters
Placebo Single Bolus Divided Dose P value
Weight, kg 31.2±1.0 34.9±1.7 32.6±1.3 0.193
Troponin-I at Day 2, ng/mL 96.4±25.5 90.0±18.7 108.6±5.1 0.695
LVEF before MI, % 64.0±1.0 65.7±1.1 64.6±1.3 0.561
LVEF at Day 2, % 41.0±1.1 41.7±0.7 39.6±0.8 0.162
LVEF at Day 28, % 40.6±1.3 47.1±1.1 43.3±1.0 0.010
Change in LVEF from Day 0 to 2, % -23.0±1.5 -24.0±1.3 -25.0±1.9 0.594
Change in LVEF from Day 2 to 28, % -0.4±0.6 5.4±0.9 3.7±0.7 0.003
Anterior Wall Thickening at Day 28, % 21.6±7.5 44.1±3.2 30.1±2.4 0.019
Inferior Wall Thickening at Day 28, % 66.2±4.1 70.0±3.7 62.7±1.8 0.386
Anterior/Inferior Thickening Ratio at Day 28 31.5±10.2 63.2±4.0 47.8±3.3 0.012
Wall Motion Score Index (WMSI) at Day 2 1.71±0.21 1.70±0.18 1.74±0.25 0.949
Wall Motion Score Index (WMSI) at Day 28 1.70±0.17 1.38±0.11 1.35±0.12 0.001
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